Mohamed Darif

1.3k total citations
27 papers, 791 citations indexed

About

Mohamed Darif is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Mohamed Darif has authored 27 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 9 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Oncology. Recurrent topics in Mohamed Darif's work include Lymphoma Diagnosis and Treatment (13 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Mohamed Darif is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Mohamed Darif collaborates with scholars based in United States, United Kingdom and Germany. Mohamed Darif's co-authors include Leo I. Gordon, Thomas E. Witzig, Christos Emmanouilides, Arturo Molina, Katie D. Vo, Russell J. Schilder, G. Wiseman, Ian W. Flinn, Gregory A. Wiseman and Myron S. Czuczman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mohamed Darif

27 papers receiving 769 citations

Peers

Countries citing papers authored by Mohamed Darif

Since Specialization

Citations

This map shows the geographic impact of Mohamed Darif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Darif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Darif more than expected).

Fields of papers citing papers by Mohamed Darif

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamed Darif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Darif. The network helps show where Mohamed Darif may publish in the future.

Co-authorship network of co-authors of Mohamed Darif

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Darif. A scholar is included among the top collaborators of Mohamed Darif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Darif. Mohamed Darif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial 2022 ·Blood Cancer Journal ·Meletios Α. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, (unknown), Hang Quach, Xavier Leleu, (unknown), Karthik Ramasamy, Alessandra Pompa, Mark‐David Levin, Cindy Lee, (unknown), Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, (unknown), Mohamed Darif, Shaji Kumar	15
2	Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC) 2019 ·Annals of Oncology ·Toni K. Choueiri, Judit Kocsis, Russell K. Pachynski, Alexandr Poprach, (unknown), Yousef Zakharia, Primo N. Lara, Sumanta K. Pal, Lajos Géczi, Thai H. Ho, L. Mangel, Bruce G. Redman, Christopher W. Ryan, Thomas Olencki, (unknown), (unknown), (unknown), Mohamed Darif, Charles P. Theuer, Neeraj Agarwal	4
3	Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial. 2018 ·Journal of Clinical Oncology ·Eric J. Small, Fred Saad, Dana E. Rathkopf, Boris Hadaschik, Simon Chowdhury, Margaret K. Yu, Angela Lopez‐Gitlitz, (unknown), Youyi Shu, Mohamed Darif, Matthew R. Smith	4
4	Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM) 2017 ·Blood ·Habte Yimer, Jason M. Melear, Edward A. Faber, William Bensinger, John M. Burke, Sriya Gunawardena, Séan Murphy, (unknown), Yana Lutska, Mohamed Darif, Anil Londhe, Ming Qi, Jon Ukropec, Thomas S. Lin, Robert M. Rifkin	5
5	TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) 2016 ·Annals of Oncology ·K.N. Chi, S. Chowdhury, Piotr Radziszewski, Thierry Lebrét, Mustafa Özgüroğlu, Cora N. Sternberg, Robert B. Sims, (unknown), Vahid Naini, Mohamed Darif, Axel S. Merseburger	8
6	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors 2014 ·Investigational New Drugs ·Margaret von Mehren, Carolyn D. Britten, (unknown), Wayne Saville, Artemios B. Vassos, Sarah Harris, Gerald R. Galluppi, Mohamed Darif, Zev A. Wainberg, Roger B. Cohen, Stephen Leong	16
7	Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy 2007 ·Journal of Clinical Oncology ·Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Stephen Revell, Katie D. Vo, Arturo Molina	93
8	Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan 2007 ·Cancer ·Thomas E. Witzig, Arturo Molina, Leo I. Gordon, Christos Emmanouilides, Russell J. Schilder, Ian W. Flinn, Mohamed Darif, Roger M. Macklis, Katie D. Vo, Gregory A. Wiseman	136
9	Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2007 ·Clinical Lymphoma & Myeloma ·Gregory A. Wiseman, Peter S. Conti, Katie D. Vo, Russell J. Schilder, Leo I. Gordon, Christos Emmanouilides, D.H.S. Silverman, Thomas E. Witzig, Mohamed Darif, Arturo Molina	4
10	Characteristics of Patients with Stage I Follicular Lymphoma (FL) Selected for Watchful Waiting (WW) in the US: Report from the National LymphoCare Study (NLCS). 2007 ·Blood ·Jonathan W. Friedberg, Elaine K. Wong, Michael Taylor, (unknown), Mohamed Darif, Hildy Dillon	1
11	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma 2006 ·Leukemia & lymphoma ·Christos Emmanouilides, Thomas E. Witzig, Leo I. Gordon, Katie D. Vo, Gregory A. Wiseman, Ian W. Flinn, Mohamed Darif, Russell J. Schilder, Arturo Molina	65
12	Analysis of the Incidence of Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Registration and Compassionate-Use Trials of Ibritumomab Tiuxetan Radioimmunotherapy (RIT). 2006 ·Blood ·Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, (unknown), Katie D. Vo, Arturo Molina	9
13	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis 2005 ·Journal of the American Academy of Dermatology ·Alan Menter, Jennifer Clay Cather, Diane R. Baker, (unknown), Mark Lebwohl, Mohamed Darif	31
14	An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy 2005 ·Clinical Therapeutics ·Bernard S. Goffe, Kim Papp, David Gratton, Gerald G. Krueger, Mohamed Darif, Sophia Lee, Carmen Bozic, Marianne T. Sweetser, Barry Ticho	44
15	Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Is a Safe and Effective Treatment Option for Older Patients with Relapsed or Refractory Low-Grade Non-Hodgkin’s Lymphoma (NHL) 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Ruby F. Meredith, Russell J. Schilder, Christos Emmanouilides, Katie D. Vo, Thomas E. Witzig, Ian W. Flinn, Mohamed Darif, Leo I. Gordon, A. Molina	3
16	Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma 2004 ·Clinical Lymphoma ·Leo I. Gordon, Thomas E. Witzig, Arturo Molina, Myron S. Czuczman, Christos Emmanouilides, Robin Joyce, Katie D. Vo, Charles P. Theuer, Brad Pohlman, Nancy L. Bartlett, G. Wiseman, Mohamed Darif, Christine A. White	82
17	Treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy at first relapse in patients with B-cell non-Hodgkin’s lymphoma is associated with higher response rates and longer durations of response than as a more delayed treatment option: Results from a retrospective analysis 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Christos Emmanouilides, D.H.S. Silverman, T.E. Witzig, Mohamed Darif, Russell J. Schilder, Paul Foster, A. Molina	2
18	Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 (⁹⁰Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL) 2004 ·Journal of Clinical Oncology ·Leo I. Gordon, A. Molina, Christos Emmanouilides, Andrew Raubitschek, Mohamed Darif, Russell J. Schilder, Gregory A. Wiseman, Christine A. White, Thomas E. Witzig	1
19	Epidemiology of reproductive and hormonal factors in thyroid cancer: Evidence from a case‐control study in the Middle East 2001 ·International Journal of Cancer ·Anjum Memon, Mohamed Darif, Khalid Alsaleh, (unknown)	71
20	Statistical analysis of proliferative index data in clinical trials 1994 ·Statistics in Medicine ·Patricia M. Grambsch, Thomas A. Louis, Roberd M. Bostick, Greg Grandits, Lisa Fosdick, Mohamed Darif, John D. Potter	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact